European DNA vaccine market was valued at $289.2 million in 2025 and is projected to reach $446.0 million by 2035, registering a CAGR of 4.5% during the forecast period from 2026 to 2035. The market is gaining strategic momentum as rising infectious disease incidence and sustained oncology burden drive demand for innovative immunization platforms. DNA vaccines offer advantages in stability, rapid design, and scalable plasmid-based manufacturing, aligning well with Europe’s preparedness frameworks and biotechnology capabilities. Increasing antimicrobial resistance, recurring zoonotic threats, and expanding cancer immunotherapy research are reinforcing interest in next-generation vaccine technologies, including plasmid DNA-based platforms. At the same time, regulatory clarity and structured funding under EU health and research programs are improving the pathway from preclinical development to clinical validation. These factors collectively support growth across both human and animal DNA vaccine segments, particularly in infectious diseases and oncology applications.
Browse the full report description of “European DNA Vaccine Market Size, Share & Trends Analysis Report by Type (Animal DNA Vaccine, and Human DNA Vaccine), by Technology (Plasmid DNA Vaccines Technology, and Plasmid DNA Delivery Technology), by Application (Oncology, Infectious Diseases, and Others), Forecast Period 2026-2035” at https://www.omrglobal.com/industry-reports/european-dna-vaccines-market
According to the European Centre for Disease Prevention and Control (ECDC), over 35,000 deaths annually in the EU/EEA are attributable to antimicrobial-resistant infections, with updated surveillance reports in 2024 confirming sustained pressure on public health systems. The World Health Organization (WHO Europe) reported in 2024 that cancer remains the second leading cause of death in the region, accounting for nearly 1.3 million deaths per year, reinforcing the need for advanced immunotherapeutic approaches. In parallel, the European Commission continues to allocate multi-billion-euro funding under Horizon Europe (2021–2027), with substantial portions directed toward biotechnology, vaccine platforms, and genomic health innovation. Furthermore, the European Medicines Agency (EMA) has maintained updated scientific guidance on nucleic acid-based vaccines, including plasmid DNA constructs for veterinary use, signaling regulatory alignment with DNA vaccine technologies.
Market Coverage
Key questions addressed by the report.
European DNA vaccine Market Report Segment
By Type
By Technology
By Application
European DNA vaccine Market Report Segment by Country
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/european-dna-vaccines-market